These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24988933)

  • 21. Cetuximab in metastatic colorectal cancer.
    Broadbridge VT; Karapetis CS; Price TJ
    Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reply to letter: "Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)".
    Sorbye H; Mauer M; Nordlinger B
    Ann Surg; 2015 Jan; 261(1):e29. PubMed ID: 24646558
    [No Abstract]   [Full Text] [Related]  

  • 23. Cetuximab or bevacizumab in metastatic colorectal cancer?
    Sclafani F; Cunningham D
    Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
    [No Abstract]   [Full Text] [Related]  

  • 24. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'.
    Bibeau F; Gil H; Castan F; Boissière-Michot F
    Br J Cancer; 2013 Dec; 109(12):3127-9. PubMed ID: 24157831
    [No Abstract]   [Full Text] [Related]  

  • 27. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
    Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    Sotelo MJ; García-Paredes B; Aguado C; Sastre J; Díaz-Rubio E
    World J Gastroenterol; 2014 Apr; 20(15):4208-19. PubMed ID: 24764659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G; Longo F
    Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract]   [Full Text] [Related]  

  • 30. Metastatic colorectal cancer: current systemic treatment options.
    Board RE; Valle JW
    Drugs; 2007; 67(13):1851-67. PubMed ID: 17722954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.
    Elsoueidi R; Craig J; Mourad H; Richa EM
    J Natl Compr Canc Netw; 2014 Feb; 12(2):155-60. PubMed ID: 24586077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response phenotype as a predictive biomarker to guide treatment with targeted therapies.
    Oxnard GR; Schwartz LH
    J Clin Oncol; 2013 Oct; 31(30):3739-41. PubMed ID: 24043750
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
    Rodriguez NA; Ascaso FJ
    J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
    [No Abstract]   [Full Text] [Related]  

  • 35. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
    Price TJ; Townsend AR; Peeters M
    Lancet Oncol; 2014 Dec; 15(13):e582-e583. PubMed ID: 25456374
    [No Abstract]   [Full Text] [Related]  

  • 36. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
    Petrelli F; Coinu A; Barni S
    Lancet Oncol; 2014 Dec; 15(13):e581-e582. PubMed ID: 25456373
    [No Abstract]   [Full Text] [Related]  

  • 37. FOLFIRI with cetuximab or bevacizumab: FIRE-3.
    Pietrantonio F; Iacovelli R; Di Bartolomeo M; de Braud F
    Lancet Oncol; 2014 Dec; 15(13):e581. PubMed ID: 25456372
    [No Abstract]   [Full Text] [Related]  

  • 38. [New drugs for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Praxis (Bern 1994); 2004 Sep; 93(36):1455-9. PubMed ID: 15487860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
    Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
    Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
    Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.